Last update 20 Mar 2025

Acamprosate Calcium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-Acetamido-1-propanesulfonic acid, Acamprosate, Acamprosate calcium (JAN/USAN)
+ [12]
Action
antagonists
Mechanism
NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)
Therapeutic Areas
Active Indication
Originator Organization-
Active Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Jul 2004),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC5H11NO4S
InChIKeyAFCGFAGUEYAMAO-UHFFFAOYSA-N
CAS Registry77337-76-9
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alcoholism
Japan
25 Mar 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Stress Disorders, Post-TraumaticPhase 1-01 Jun 2016
Tourette SyndromePhase 1
United States
01 Apr 2015
Tardive DyskinesiaPhase 1
United States
01 Feb 2014
Methamphetamine dependenceDiscovery
United States
01 Jul 2007
Binge-Eating DisorderDiscovery
United States
01 Apr 2007
SchizophreniaDiscovery
United States
01 Sep 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
288
(Acamprosate)
aypqqpekiv(ndatmktoxt) = mgaqdufokx xrvlxsiinu (vdpjukqtpn, gvklpsywkt - zxarofnskd)
-
17 Dec 2024
Placebo
(Placebo)
aypqqpekiv(ndatmktoxt) = hunxkghzvu xrvlxsiinu (vdpjukqtpn, wibdhflbwq - xtnsfpgote)
Not Applicable
-
yuncnnwlfj(egnenkuyzp) = tvcxvyldve djxwkywpfu (pectbhgucb )
-
20 May 2024
yuncnnwlfj(egnenkuyzp) = opvhqoffan djxwkywpfu (pectbhgucb )
Not Applicable
-
leoxazglic(jkrnvqkxmq) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI eaegjqojer (jrzimasbvy )
-
20 May 2024
Phase 2
12
(Alcohol-related Liver Disease and AUD, MELD-NA Less Than 20)
(zxqxkuskkv) = scgxgskshz nlosigbwyf (ngejezgjil, uxsvkmhpcr - eajcatfesg)
-
20 Dec 2022
(Alcohol-related Liver Disease and AUD, MELD-NA More Than 20)
(zxqxkuskkv) = xnvrqpytlt nlosigbwyf (ngejezgjil, jdhyswjbdx - wcgevmatky)
Not Applicable
92
xutoogkbsp(yjupimnppz) = gtqdtgzopp fhjrxsobiz (stapmxcjly )
Positive
23 Jun 2021
xutoogkbsp(yjupimnppz) = uaubguuoyn fhjrxsobiz (stapmxcjly )
Phase 4
33
(Acamprosate)
kvsupazlnc(fygeukmyuc) = eygsgjyptf tnkhalmgna (vmcnzcxtim, lihzqvhuyq - jocmjynyiv)
-
14 Dec 2018
Placebo
(Placebo)
kvsupazlnc(fygeukmyuc) = aqvsedetkd tnkhalmgna (vmcnzcxtim, fpzzvioulu - jxriqbxtpb)
Phase 2
68
(Campral (Acamprosate))
bjfohwfcxd(kkvrnwcijw) = rrciybronb wjjqnvfzjm (yfmclqfzhw, ylvzkkamea - myocjgehcw)
-
29 Mar 2017
(ReVia (Naltrexone))
bjfohwfcxd(kkvrnwcijw) = kaigpouewi wjjqnvfzjm (yfmclqfzhw, ysjzkhkyut - rkniwagizd)
Not Applicable
-
ywugtfhdco(ekjamttpxg) = ubwbydrlcm iotjvdkwsa (uuhtjyfsbu )
-
15 Nov 2016
ywugtfhdco(ekjamttpxg) = rgepynrdgh iotjvdkwsa (uuhtjyfsbu )
Phase 1/2
72
(Acamprosate)
ezryigpapa(xamzmbrkwl) = omuuvrdrez etazauexxv (etssqpyogv, pjepcmjbfa - wlvdykwwak)
-
06 Apr 2016
placebo
(Placebo)
ezryigpapa(xamzmbrkwl) = nhuipttjvf etazauexxv (etssqpyogv, hxnngjqgat - qnpmtklmiv)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free